Details of the Drug

General Information of Drug (ID: DMNH3PG)

Drug Name
Etoposide
Synonyms
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 588.6
Topological Polar Surface Area (xlogp) 0.6
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 13
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.5 mL/min/kg [4]
Elimination
38% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.7 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.2986 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.12% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.18 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.22 mg/mL [3]
Chemical Identifiers
Formula
C29H32O13
IUPAC Name
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Canonical SMILES
C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
InChI
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
InChIKey
VJJPUSNTGOMMGY-MRVIYFEKSA-N
Cross-matching ID
PubChem CID
36462
ChEBI ID
CHEBI:4911
CAS Number
33419-42-0
DrugBank ID
DB00773
TTD ID
D0B7EB
VARIDT ID
DR00162
INTEDE ID
DR0669
ACDINA ID
D00258

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [9]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [15]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [16]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [17]
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Substrate [18]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [18]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [19]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Etoposide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Etoposide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [145]
Armodafinil DMGB035 Minor Increased metabolism of Etoposide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [146]
LEE011 DMMX75K Moderate Decreased metabolism of Etoposide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [147]
Doxorubicin DMVP5YE Minor Increased renal excretion of Etoposide caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [148]
Coadministration of a Drug Treating the Disease Different from Etoposide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Decreased clearance of Etoposide due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [149]
Arn-509 DMT81LZ Moderate Accelerated clearance of Etoposide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [149]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Etoposide due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [145]
Dronedarone DMA8FS5 Moderate Decreased clearance of Etoposide due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [150]
Posaconazole DMUL5EW Moderate Decreased metabolism of Etoposide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [149]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Etoposide and Roflumilast. Asthma [CA23] [149]
Ofloxacin DM0VQN3 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [151]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Etoposide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [152]
Sparfloxacin DMB4HCT Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [151]
Gemifloxacin DMHT34O Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [151]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [151]
ABT-492 DMJFD2I Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [151]
Levofloxacin DMS60RB Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [151]
Lomefloxacin DMVRH9C Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [151]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Etoposide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [153]
Erdafitinib DMI782S Moderate Decreased clearance of Etoposide due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [154]
Lapatinib DM3BH1Y Moderate Decreased clearance of Etoposide due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [155]
Tucatinib DMBESUA Moderate Decreased metabolism of Etoposide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [156]
PF-04449913 DMSB068 Moderate Decreased clearance of Etoposide due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [149]
Anisindione DM2C48U Moderate Increased plasma concentration of Etoposide and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [157]
Mifepristone DMGZQEF Moderate Decreased metabolism of Etoposide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [145]
Ivacaftor DMZC1HS Moderate Decreased clearance of Etoposide due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [158]
MK-8228 DMOB58Q Moderate Decreased metabolism of Etoposide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [159]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Etoposide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [160]
Primidone DM0WX6I Moderate Increased metabolism of Etoposide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [161]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Etoposide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [161]
Cenobamate DMGOVHA Moderate Increased metabolism of Etoposide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [162]
Stiripentol DMMSDOY Moderate Decreased metabolism of Etoposide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [163]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Etoposide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [161]
Rufinamide DMWE60C Moderate Increased metabolism of Etoposide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [149]
Phenobarbital DMXZOCG Moderate Increased metabolism of Etoposide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [161]
Tazemetostat DMWP1BH Moderate Increased metabolism of Etoposide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [164]
Itraconazole DMCR1MV Moderate Decreased metabolism of Etoposide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [165]
Boceprevir DMBSHMF Moderate Decreased metabolism of Etoposide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [166]
Telaprevir DMMRV29 Moderate Decreased metabolism of Etoposide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [167]
GS-5885 DMSL3DX Moderate Decreased clearance of Etoposide due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [168]
Rifapentine DMCHV4I Moderate Increased metabolism of Etoposide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [169]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Etoposide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [170]
Saquinavir DMG814N Moderate Decreased metabolism of Etoposide caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [171]
Etravirine DMGV8QU Moderate Increased metabolism of Etoposide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [172]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Etoposide and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [173]
Darunavir DMN3GCH Moderate Decreased metabolism of Etoposide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [174]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Etoposide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [175]
Conivaptan DM1V329 Moderate Decreased metabolism of Etoposide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [176]
Tolvaptan DMIWFRL Moderate Decreased clearance of Etoposide due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [145]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Etoposide and Denosumab. Low bone mass disorder [FB83] [177]
Brigatinib DM7W94S Moderate Increased metabolism of Etoposide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [178]
Ceritinib DMB920Z Moderate Decreased metabolism of Etoposide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [149]
PF-06463922 DMKM7EW Moderate Increased metabolism of Etoposide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [179]
Capmatinib DMYCXKL Moderate Decreased clearance of Etoposide due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [180]
Selpercatinib DMZR15V Moderate Decreased metabolism of Etoposide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [149]
Idelalisib DM602WT Moderate Decreased metabolism of Etoposide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [181]
IPI-145 DMWA24P Moderate Decreased metabolism of Etoposide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [182]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Etoposide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [149]
Lasmiditan DMXLVDT Moderate Decreased clearance of Etoposide due to the transporter inhibition by Lasmiditan. Migraine [8A80] [183]
Exjade DMHPRWG Moderate Decreased metabolism of Etoposide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [184]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Etoposide and Thalidomide. Multiple myeloma [2A83] [185]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Etoposide and Tecfidera. Multiple sclerosis [8A40] [186]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Etoposide and Siponimod. Multiple sclerosis [8A40] [145]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Etoposide and Fingolimod. Multiple sclerosis [8A40] [187]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Etoposide and Ocrelizumab. Multiple sclerosis [8A40] [188]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Etoposide and Ozanimod. Multiple sclerosis [8A40] [149]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Etoposide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [149]
Nilotinib DM7HXWT Moderate Decreased metabolism of Etoposide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [189]
Dasatinib DMJV2EK Moderate Decreased metabolism of Etoposide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [190]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Etoposide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [191]
Rolapitant DM8XP26 Moderate Decreased clearance of Etoposide due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [192]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Etoposide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [193]
Abametapir DM2RX0I Moderate Decreased metabolism of Etoposide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [194]
Lefamulin DME6G97 Moderate Decreased metabolism of Etoposide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [195]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Etoposide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [196]
Enzalutamide DMGL19D Moderate Accelerated clearance of Etoposide due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [197]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Etoposide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [198]
Gatifloxacin DMSL679 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [151]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Etoposide and Canakinumab. Rheumatoid arthritis [FA20] [199]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Etoposide and Rilonacept. Rheumatoid arthritis [FA20] [199]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Etoposide and Golimumab. Rheumatoid arthritis [FA20] [200]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Etoposide and Leflunomide. Rheumatoid arthritis [FA20] [175]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Etoposide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [201]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Etoposide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [202]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Etoposide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [149]
Pitolisant DM8RFNJ Moderate Increased metabolism of Etoposide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [149]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Etoposide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [203]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Etoposide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [198]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Etoposide and Azathioprine. Transplant rejection [NE84] [145]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Etoposide and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [198]
Cinoxacin DM4EWNS Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [151]
Nalidixic acid DMRM0JV Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [151]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Etoposide and Ganciclovir. Virus infection [1A24-1D9Z] [145]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Etoposide and Valganciclovir. Virus infection [1A24-1D9Z] [145]
⏷ Show the Full List of 90 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Eisenoxyd E00585 56841934 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Dextran E00466 4125253 Lyophilization aid
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Etoposide 50 mg capsule 50 mg Oral Capsule Oral
Etoposide Phosphate eq 100mg base/vial injectable eq 100mg base/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
7 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
8 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
9 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
10 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
11 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
12 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
13 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
16 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
17 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
18 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
19 Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
20 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
21 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
22 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
23 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
24 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
25 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
29 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
30 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
31 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
32 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
33 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
34 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
35 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
36 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
37 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
38 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
39 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
40 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
41 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
42 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
43 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
44 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
45 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
46 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
47 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
48 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
49 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
50 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
51 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
52 Drug Interactions Flockhart Table
53 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
54 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
55 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
56 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
57 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
58 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
59 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
60 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
61 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
62 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
63 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
64 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
65 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
66 Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
67 Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
68 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
69 Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
70 The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
71 Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
72 Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
73 Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
74 PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
75 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
76 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
77 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
78 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
79 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
80 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
81 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
82 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
83 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
84 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
85 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
86 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
87 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
88 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
89 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
90 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
91 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
92 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
93 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
94 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
95 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
96 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
97 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
98 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
99 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
100 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
101 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
102 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
103 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
104 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
105 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
106 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
107 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
108 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
109 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
110 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
111 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
112 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
113 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
114 FDA Drug Development and Drug Interactions
115 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
116 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
117 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
118 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
119 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
120 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
121 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
122 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
123 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
124 Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
125 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
126 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
127 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
128 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
129 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
130 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
131 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
132 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
133 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
134 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
135 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
136 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
137 Drug Interactions in Infectious Diseases.
138 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
139 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
140 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
141 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
142 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
143 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
144 Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
145 Cerner Multum, Inc. "Australian Product Information.".
146 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
147 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
148 Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M "Influence of polysorbate 80 (tween 80) and etoposide (VP-16-213 on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients." Cancer Chemother Pharmacol 17 (1987): 80-4. [PMID: 3698181]
149 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
150 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
151 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
152 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
153 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
154 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
155 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
156 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
157 Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
158 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
159 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
160 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
161 Rodman JH, Murry DJ, Madden T, Santana VM "Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation." J Clin Oncol 12 (1994): 2390-7. [PMID: 7964955]
162 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
163 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
164 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
165 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
166 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
167 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
168 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
169 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
170 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
171 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
172 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
173 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
174 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
175 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
176 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
177 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
178 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
179 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
180 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
181 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
182 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
183 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
184 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
185 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
186 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
187 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
188 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
189 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
190 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
191 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
192 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
193 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
194 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
195 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
196 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
197 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
198 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
199 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
200 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
201 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
202 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
203 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.